937 related articles for article (PubMed ID: 9286184)
1. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
[TBL] [Abstract][Full Text] [Related]
2. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Glazer WM
J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
[TBL] [Abstract][Full Text] [Related]
3. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
Beasley CM; Dellva MA; Tamura RN; Morgenstern H; Glazer WM; Ferguson K; Tollefson GD
Br J Psychiatry; 1999 Jan; 174():23-30. PubMed ID: 10211147
[TBL] [Abstract][Full Text] [Related]
4. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis.
Miller DD; Eudicone JM; Pikalov A; Kim E
J Clin Psychiatry; 2007 Dec; 68(12):1901-6. PubMed ID: 18162021
[TBL] [Abstract][Full Text] [Related]
5. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
8. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
10. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
Oosthuizen PP; Emsley RA; Maritz JS; Turner JA; Keyter N
J Clin Psychiatry; 2003 Sep; 64(9):1075-80. PubMed ID: 14628983
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
[TBL] [Abstract][Full Text] [Related]
12. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
Costa e Silva JA; Alvarez N; Mazzotti G; Gattaz WF; Ospina J; Larach V; Starkstein S; Oliva D; Cousins L; Tohen M; Taylor CC; Wang J; Tran PV
J Clin Psychopharmacol; 2001 Aug; 21(4):375-81. PubMed ID: 11476121
[TBL] [Abstract][Full Text] [Related]
13. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.
Berk M; Brook S; Trandafir AI
Int Clin Psychopharmacol; 1999 May; 14(3):177-80. PubMed ID: 10435771
[TBL] [Abstract][Full Text] [Related]
14. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia.
Emsley R; Turner HJ; Schronen J; Botha K; Smit R; Oosthuizen PP
J Clin Psychiatry; 2004 May; 65(5):696-701. PubMed ID: 15163258
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
[TBL] [Abstract][Full Text] [Related]
17. [Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].
Szafrański T
Psychiatr Pol; 2014; 48(6):1155-65. PubMed ID: 25717485
[TBL] [Abstract][Full Text] [Related]
18. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.
Brar JS; Parepally H; Chalasani L; Gopalani A; Appel N; Chengappa KN
Ann Clin Psychiatry; 2008; 20(3):139-44. PubMed ID: 18633740
[TBL] [Abstract][Full Text] [Related]
19. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
[TBL] [Abstract][Full Text] [Related]
20. Tardive dyskinesia in affective disorders.
Kane JM
J Clin Psychiatry; 1999; 60 Suppl 5():43-7; discussion 48-9. PubMed ID: 10192407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
